Moderna Initiates Phase 1/2 Trial for Multiple Myeloma Therapy

Moderna, Inc. has announced the commencement of a Phase 1/2 trial for its investigational mRNA-based T-cell engager, mRNA-2808, aimed at participants with relapsed or refractory multiple myeloma (RRMM). The first dose was administered at SCRI Oncology Partners in Nashville, Tennessee, in collaboration with the Sarah Cannon Research Institute.

mRNA-2808 employs a multiplexed therapy encoding three T-cell engagers targeting myeloma-associated antigens. This approach seeks to tackle tumor heterogeneity and known resistance mechanisms. Dr. Kyle Holen of Moderna highlighted the milestone's significance, emphasizing the potential impact of innovative therapies in tackling unmet needs in multiple myeloma.

Dr. Hans Lee of SCRI emphasized the complexity of multiple myeloma and expressed hope in mRNA-based therapies' potential to redefine cancer treatment. The study evaluates the safety and tolerability of mRNA-2808 in patients aged 18 and older.